Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis.
Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and improve treatment efficacy. In the current study, we evaluated the effects of a combination treatment consisting of inhalation of aerosolized liposomal amphotericin B (L-AMB) with intraperitoneal administration of micafungin (MCFG) against murine invasive pulmonary aspergillosis. The combination of aerosolized L-AMB with intraperitoneal MCFG significantly improved the survival rate, and the fungal burdens and histopathology findings after this treatment were superior to those of the control and both monotherapy groups.
Takazono
Takahiro
T
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Izumikawa
Koichi
K
Mihara
Tomo
T
Kosai
Kosuke
K
Saijo
Tomomi
T
Imamura
Yoshifumi
Y
Miyazaki
Taiga
T
Seki
Masafumi
M
Kakeya
Hiroshi
H
Yamamoto
Yoshihiro
Y
Yanagihara
Katsunori
K
Kohno
Shigeru
S
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D007274:Injections, Intraperitoneal; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy* / Q000473:pathology; D055666:Lipopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D000077551:Micafungin; D051379:Mice; D008813:Mice, Inbred ICR
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077551:Micafungin